9 research outputs found
Statistical Channel Impulse Response Modeling for Optical Wireless Communication in Turbid Waters
Underwater optical wireless communication (UOWC) systems support high-speed, reliable and cost-effective implementations that are demanded for extending the telecommunication networks to oceans. UOWC systems suffer from attenuation and scattering processes. Particularly, the scattering process can change the direction of the emitted photons, especially in turbid waters. In this way, quantifying the signal attenuation and the time dispersion produced by absorption and scattering is a crucial work. Hence, we propose a new closed-form solution for modeling the channel impulse response for UOWC systems in turbid water that is validated through Monte Carlo simulations and can be used for system design and optimization purposes.Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech
In silico Design of an Epitope-Based Vaccine Ensemble for Chagas Disease
Trypanosoma cruzi infection causes Chagas disease, which affects 7 million people
worldwide. Two drugs are available to treat it: benznidazole and nifurtimox. Although
both are efficacious against the acute stage of the disease, this is usually asymptomatic
and goes undiagnosed and untreated. Diagnosis is achieved at the chronic stage, when
life-threatening heart and/or gut tissue disruptions occur in ∼30% of those chronically
infected. By then, the drugs’ efficacy is reduced, but not their associated high toxicity.
Given current deficiencies in diagnosis and treatment, a vaccine to prevent infection
and/or the development of symptoms would be a breakthrough in the management
of the disease. Current vaccine candidates are mostly based on the delivery of single
antigens or a few different antigens. Nevertheless, due to the high biological complexity
of the parasite, targeting as many antigens as possible would be desirable. In this
regard, an epitope-based vaccine design could be a well-suited approach. With this
aim, we have gone through publicly available databases to identify T. cruzi epitopes
from several antigens. By means of a computer-aided strategy, we have prioritized a
set of epitopes based on sequence conservation criteria, projected population coverage
of Latin American population, and biological features of their antigens of origin. Fruit of
this analysis, we provide a selection of CD8+ T cell, CD4+ T cell, and B cell epitopes that
have <70% identity to human or human microbiome protein sequences and represent
the basis toward the development of an epitope-based vaccine against T. cruzi
Impulse Response Modeling of Underwater Optical Scattering Channels for Wireless Communication
In silico Design of an Epitope-Based Vaccine Ensemble for Chagas Disease
International audienceTrypanosoma cruzi infection causes Chagas disease, which affects 7 million people worldwide. Two drugs are available to treat it: benznidazole and nifurtimox. Although both are efficacious against the acute stage of the disease, this is usually asymptomatic and goes undiagnosed and untreated. Diagnosis is achieved at the chronic stage, when life-threatening heart and/or gut tissue disruptions occur in similar to 30% of those chronically infected. By then, the drugs' efficacy is reduced, but not their associated high toxicity. Given current deficiencies in diagnosis and treatment, a vaccine to prevent infection and/or the development of symptoms would be a breakthrough in the management of the disease. Current vaccine candidates are mostly based on the delivery of single antigens or a few different antigens. Nevertheless, due to the high biological complexity of the parasite, targeting as many antigens as possible would be desirable. In this regard, an epitope-based vaccine design could be a well-suited approach. With this aim, we have gone through publicly available databases to identify T. cruzi epitopes from several antigens. By means of a computer-aided strategy, we have prioritized a set of epitopes based on sequence conservation criteria, projected population coverage of Latin American population, and biological features of their antigens of origin. Fruit of this analysis, we provide a selection of CD8(+) T cell, CD4(+) T cell, and B cell epitopes that have T. cruzi
Experimental study on the performance of a mechanical cooling tower fitted with different types of water distribution systems and drift eliminators
Clinical profile and mortality in patients with T. Cruzi/HIV co-infection from the multicenter data base of the "network for healthcare and study of trypanosoma cruzi/HIV co-infection and other immunosuppression conditions"
Chagas disease (CD) globalization facilitated the co-infection with Human Immunodeficiency Virus (HIV) in endemic and non-endemic areas. Considering the underestimation of Trypanosoma cruzi (T. cruzi)-HIV co-infection and the risk of life-threatening Chagas Disease Reactivation (CDR), this study aimed to analyze the major co-infection clinical characteristics and its mortality rates. This is a cross-sectional retrospective multicenter study of patients with CD confirmed by two serological or one parasitological tests, and HIV infection confirmed by immunoblot. CDR was diagnosed by direct microscopy with detection of trypomastigote forms in the blood or other biological fluids and/or amastigote forms in inflammatory lesions. Out of 241 patients with co-infection, 86.7% were from Brazil, 47.5% had <200 CD4+ T cells/μL and median viral load was 17,000 copies/μL. Sixty CDR cases were observed. Death was more frequent in patients with reactivation and was mainly caused by CDR. Other causes of death unrelated to CDR were the manifestation of opportunistic infections in those with Acquired Immunodeficiency Syndrome. The time between the co-infection diagnosis to death was shorter in patients with CDR. Lower CD4+ cells count at co-infection diagnosis was independently associated with reactivation. Similarly, lower CD4+ cells numbers at co-infection diagnosis and male sex were associated with higher lethality in CDR. Additionally, CD4+ cells were lower in meningoencephalitis than in myocarditis and milder forms. This study showed major features on T. cruzi-HIV co-infection and highlighted the prognostic role of CD4+ cells for reactivation and mortality. Since lethality was high in meningoencephalitis and all untreated patients died shortly after the diagnosis, early diagnosis, immediate antiparasitic treatment, patient follow-up and epidemiological surveillance are essentials in T. cruzi/HIV co-infection and CDR managements
Clinical profile and mortality in patients with T. cruzi/HIV co-infection from the multicenter data base of the "Network for healthcare and study of Trypanosoma cruzi/HIV co-infection and other immunosuppression conditions".
ObjectiveChagas disease (CD) globalization facilitated the co-infection with Human Immunodeficiency Virus (HIV) in endemic and non-endemic areas. Considering the underestimation of Trypanosoma cruzi (T. cruzi)-HIV co-infection and the risk of life-threatening Chagas Disease Reactivation (CDR), this study aimed to analyze the major co-infection clinical characteristics and its mortality rates.MethodsThis is a cross-sectional retrospective multicenter study of patients with CD confirmed by two serological or one parasitological tests, and HIV infection confirmed by immunoblot. CDR was diagnosed by direct microscopy with detection of trypomastigote forms in the blood or other biological fluids and/or amastigote forms in inflammatory lesions.ResultsOut of 241 patients with co-infection, 86.7% were from Brazil, 47.5% had ConclusionThis study showed major features on T. cruzi-HIV co-infection and highlighted the prognostic role of CD4+ cells for reactivation and mortality. Since lethality was high in meningoencephalitis and all untreated patients died shortly after the diagnosis, early diagnosis, immediate antiparasitic treatment, patient follow-up and epidemiological surveillance are essentials in T. cruzi/HIV co-infection and CDR managements
Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry
Altres ajuts: Fondo Europeo de Desarrollo Regional (FEDER); Agencia Española del Medicamento; Consejería de Salud de Andalucía.Background & Aims: Prospective drug-induced liver injury (DILI) registries are important sources of information on idiosyncratic DILI. We aimed to present a comprehensive analysis of 843 patients with DILI enrolled into the Spanish DILI Registry over a 20-year time period. Methods: Cases were identified, diagnosed and followed prospectively. Clinical features, drug information and outcome data were collected. Results: A total of 843 patients, with a mean age of 54 years (48% females), were enrolled up to 2018. Hepatocellular injury was associated with younger age (adjusted odds ratio [aOR] per year 0.983; 95% CI 0.974-0.991) and lower platelet count (aOR per unit 0.996; 95% CI 0.994-0.998). Anti-infectives were the most common causative drug class (40%). Liver-related mortality was more frequent in patients with hepatocellular damage aged ≥65 years (p = 0.0083) and in patients with underlying liver disease (p = 0.0221). Independent predictors of liver-related death/transplantation included nR-based hepatocellular injury, female sex, higher onset aspartate aminotransferase (AST) and bilirubin values. nR-based hepatocellular injury was not associated with 6-month overall mortality, for which comorbidity burden played a more important role. The prognostic capacity of Hy's law varied between causative agents. Empirical therapy (corticosteroids, ursodeoxycholic acid and MARS) was prescribed to 20% of patients. Drug-induced autoimmune hepatitis patients (26 cases) were mainly females (62%) with hepatocellular damage (92%), who more frequently received immunosuppressive therapy (58%). Conclusions: AST elevation at onset is a strong predictor of poor outcome and should be routinely assessed in DILI evaluation. Mortality is higher in older patients with hepatocellular damage and patients with underlying hepatic conditions. The Spanish DILI Registry is a valuable tool in the identification of causative drugs, clinical signatures and prognostic risk factors in DILI and can aid physicians in DILI characterisation and management. Lay summary: Clinical information on drug-induced liver injury (DILI) collected from enrolled patients in the Spanish DILI Registry can guide physicians in the decision-making process. We have found that older patients with hepatocellular type liver injury and patients with additional liver conditions are at a higher risk of mortality. The type of liver injury, patient sex and analytical values of aspartate aminotransferase and total bilirubin can also help predict clinical outcomes